-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Protagonist Therapeutics (PTGX)
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) PT Raised to $121 at Truist Securities
-
-
-
-
-
-
-
Truist Securities models $730M peak revenue for Protagonist Therapeutics (PTGX) in Icotyde royalties
-
-
-
-
-
-
-
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Jefferies Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) January 95 calls active, share price up 32%
-
-
-
-
-
-
-
Barclays Starts Protagonist Therapeutics (PTGX) at Overweight
-
424,814 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

